Click here for the rest of the story.
The Danish drugmaker has agreed to pay $25 million to settle a whistleblower lawsuit to settle charges of off-label marketing its NovoSeven treatment to stop bleeding. As part of the settlement, Novo Nordisk has entered into a five-year Corporate Integrity Agreement and will have to beef up its compliance procedures, according to a statement from the drugmaker.
* * *
“This is a significant case, because it involves the corruption of a very important institution,” says Dan Hargrove, one of the attorneys who represents both whistleblowers in a statement. “Oftentimes in off-label cases, you don’t have patient harm. In this case, you not only have harm to the integrityof the Army, but you also have harm to our soldiers — our nation’s finest. And they deserve better.”